Hanmi Pharmaceutical’s obesity treatment Efe has cleared product approval from South Korea’s Ministry of Food and Drug Safety, according to reports by JoongAng Ilbo and Korea Economic Daily on October 7. The decision moves Efe beyond development and regulatory review, giving the domestic drugmaker a basis to prepare for entry into a market led by products such as Wegovy and Mounjaro.

The approval is the central confirmed development. It establishes that Efe received regulatory authorization as an obesity treatment, but the available reports do not establish when sales will begin, how much the treatment will cost patients, or whether it will receive insurance coverage.

Those distinctions matter for patients, prescribers and investors. Regulatory approval does not by itself confirm the timing or scale of commercial supply, and the cited reports do not provide a comparative assessment of Efe’s effectiveness or safety against competing treatments. No conclusion about superiority should therefore be drawn from the approval announcement alone.

What to watch next

The next developments to watch are Hanmi’s launch schedule, supply plans and pricing information, along with any official details on reimbursement and product use. Until those points are separately confirmed, the clearest significance of the decision is that a locally developed obesity treatment has passed a major regulatory gate and can move toward potential market entry.